about
Antibody-drug conjugates as novel anti-cancer chemotherapeuticsSpecificity delivers: therapeutic role of tumor antigen-specific antibodies in pancreatic cancerEstimating the Population Benefits and Costs of Rituximab Therapy in the United States from 1998 to 2013 Using Real-World DataAntibody Therapies in Cancer.Rituximab specifically depletes short-lived autoreactive plasma cells in a mouse model of inflammatory arthritis.Rituximab therapy reduces organ-specific T cell responses and ameliorates experimental autoimmune encephalomyelitis.Monoclonal antibodies for non-Hodgkin's lymphoma: state of the art and perspectives.B-lymphocyte-mediated delayed cognitive impairment following stroke.Disease-modifying therapies in multiple sclerosis: an update on recent and ongoing trials and future strategies.Safety of rituximab in the treatment of B cell malignancies: implications for rheumatoid arthritisImmunotherapy of ovarian cancer with antibodies: a focus on oregovomab.Recent Development in Carbohydrate Based Anti-cancer Vaccines.Monoclonal antibody therapy of ovarian cancer.Targeted therapy for hematologic malignancies.Supernatural T cells: genetic modification of T cells for cancer therapy.Evolving role of rituximab in the treatment of patients with non-Hodgkin's lymphoma.Personalized medicine and the practice of medicine in the 21st century.Rituximab for the treatment of diffuse large B-cell lymphomas.Molecularly targeted therapies for dysimmune neuropathiesAnti-CD20 as the B-Cell Targeting Agent in a Combined Therapy to Modulate Anti-Factor VIII Immune Responses in Hemophilia a Inhibitor MiceKnobs-into-holes antibody production in mammalian cell lines reveals that asymmetric afucosylation is sufficient for full antibody-dependent cellular cytotoxicity.Atacicept, a novel B cell-targeting biological therapy for the treatment of rheumatoid arthritis.Trends in therapeutic monoclonal antibodies of cancer.Rituximab: as first-line maintenance therapy following rituximab-containing therapy for follicular lymphoma.Rituximab as first-line maintenance therapy following rituximab-containing therapy for follicular lymphoma: profile report.Hepatitis C Virus-related Mixed Cryoglobulinemia: Pathogenesis, Clinica Manifestations, and New TherapiesStandard and escalating treatment of chronic inflammatory demyelinating polyradiculoneuropathy.Evaluation of therapeutic effect of tumor-targeted therapy.Effect of rituximab on peripheral blood stem cell mobilization and engraftment kinetics in non-Hodgkin's lymphoma patients.Emerging drugs for ovarian cancer
P2860
Q26800175-6988569C-A242-4704-8918-269876F73931Q26853171-9226C149-9EE6-453E-8994-A598F02505C5Q31036587-B151039D-3BEB-4093-AFAE-0A0ABB18AB9FQ31104000-5231055C-FFE9-4289-94BD-51EBF92F4993Q33740847-D7C8E4C9-DC80-4682-9AB2-6D03204B648DQ33832088-720C67C6-0A43-4087-8B6B-7BA2324691ECQ34700655-C5DFBA18-3623-4544-9A8D-368C5612BDDDQ35044819-AF8D3AD8-8BB0-4CEB-8F5B-A4C2689E8B01Q35094706-8B5797CE-BFD3-42E1-808A-317091B2E32EQ35794369-86130283-22A4-4F87-85B2-CEBA14306C66Q35842690-932AE98A-A59B-4485-8B0D-31AC04EFCD75Q35854131-2911182F-5AFD-4BB2-AF0B-D4AB243D4374Q36066157-3213F311-EA11-41A2-ACA0-C42F09B008CEQ36108610-BD2D02AE-2AB5-428D-9066-4A27ED5959E0Q36328805-67C3E366-54C1-43ED-AAE7-3BB31378948DQ36429463-55E3EC2F-0DA7-4991-81D0-DA0FD873C3EAQ36571269-8DDE2DF3-A76B-460D-86CB-70B3BD82A592Q36573823-CDCBBBC6-24B2-417C-B3F0-6E906BB4C30CQ37254545-EDF977C5-5609-4AFB-89D8-9315B212E758Q37434315-90ECF2C3-E383-4920-A678-D816A870BE06Q37496563-D481F7D2-211A-4109-A73C-3E2AA585C9AEQ37517575-D324065B-FCA5-477B-87C0-F6F83D441E99Q37689796-A3F20BCA-3738-4984-984E-4036DF069213Q37875060-BDC0D9B3-1633-47FC-B775-601541DAC121Q37937704-AC9E6021-6A62-490B-8C96-3D5A0CE7FA70Q37940987-6A416800-F979-4880-8273-44C40AA2B8C6Q41834761-B9A5326E-0A44-4ADF-8515-BCAE4BBB3513Q41962463-D25381AB-2E5C-40B0-BE02-7D9D0ED674D0Q44470469-614099CF-BB08-4ABA-9441-FBBF57CB0DBBQ57903790-C759E81F-0152-425B-AB9F-71E223DDDE0E
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Rituximab: ongoing and future clinical development.
@ast
Rituximab: ongoing and future clinical development.
@en
Rituximab: ongoing and future clinical development.
@nl
type
label
Rituximab: ongoing and future clinical development.
@ast
Rituximab: ongoing and future clinical development.
@en
Rituximab: ongoing and future clinical development.
@nl
prefLabel
Rituximab: ongoing and future clinical development.
@ast
Rituximab: ongoing and future clinical development.
@en
Rituximab: ongoing and future clinical development.
@nl
P2093
P356
P1433
P1476
Rituximab: ongoing and future clinical development.
@en
P2093
Antonio J Grillo-López
Eric Hedrick
Mark Benyunes
Michelle Rashford
P304
P356
10.1053/SONC.2002.30145
P433
P577
2002-02-01T00:00:00Z